



This is a repository copy of *Low expression and promoter hypermethylation of the tumour suppressor SLIT2, are associated with adverse patient outcomes in diffuse large B cell lymphoma.*

White Rose Research Online URL for this paper:
<https://eprints.whiterose.ac.uk/142626/>

Version: Supplemental Material

Article:

Mohamed, G. orcid.org/0000-0002-5831-4083, Talima, S., Li, L. et al. (6 more authors) (2019) Low expression and promoter hypermethylation of the tumour suppressor SLIT2, are associated with adverse patient outcomes in diffuse large B cell lymphoma. *Pathology & Oncology Research*, 25 (3). pp. 1223-1231. ISSN 1219-4956

<https://doi.org/10.1007/s12253-019-00600-9>

This is a post-peer-review, pre-copyedit version of an article published in *Pathology & Oncology Research*. The final authenticated version is available online at:
<https://doi.org/10.1007/s12253-019-00600-9>.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Table 1: Baseline pathologic and clinical characteristics of 108 DLBCL cases

Pathologic and clinical Characteristics	Number of samples (n)(%)
Age (Yrs)	
<=60	37 (34.3)
>60	71 (65.7)
Range	25-92 years
Gender	
Female	43 (39.8)
Male	65 (60.2)
DLBCL subtypes (n= 107)	
GCB	49 (45.8)
ABC/non GCB	58 (54.2)
Volume/cm	
<=10	87 (80.6)
>10	21 (19.4)
Initial tumor site	
Nodal	53 (49.1)
Extra nodal	6 (5.6)
Both sites (nodal and extranodal)	49 (45.4)
No. of extra nodal sites	
≤ 1	97 (89.8)
>1	11(10.2)
Stage (Ann Arbor staging system)	
I	26 (24.1)
II	25 (23.1)
III	24 (22.2)
IV	33 (30.6)
ECOG performance status (n= 105)	
0	67 (62.1)
I	27 (25)
II	7 (6.5)
III	3 (2.8)
IV	1 (0.9)
Not known	3 (2.7)
Pretreated LDH	
Normal	50 (46.3)
Raised	58 (53.7)
R-IPi	
Very good	0 (0)
Good	77 (71.3)
Poor	31 (28.7)
B-symptoms (n=106)	
Absent	52 (49.1)
Present	54 (50.9)
Relapse	35 (32.4)
Progression	9(8.3)
Death	19 (17.6)
Live-free	45 (41.7)

Initial Treatment	
CHOP	12 (11.1)
R-CHOP*	60 (66.5)
Palliative	19 (17.9)
Watch and wait	3 (2.8)
Others**	12 (11.1)

**RCHOP: Rituximab (Rituxan) (cyclophosphamide, doxorubicin, vincristine, and prednisone)*

***Others: Mainly relapsed & poor prognosis whose treatment is automatically upstaged to more aggressive treatment: BEAM (Carmustine, etoposide, cytarabine, and melphalan), or RICE (rituximab, ifosfamide, carboplatin, and etoposide), autograft, Salvage regime {ESHAP= (Etoposide, cytarabine, cisplatin and methylprednisolone) and DHAP= (dexamethasone, cytarabine, cisplatin) and BEAM}, Surgery only (for curative intent), RituxiMab and Radiotherapy (curative intent).*

Table 2: Correlation of SLIT2 expression with clinicopathologic features and prognostic parameters of DLBCL

Features		No.	SLIT2 protein expression		p value
			Low (n) (%) (N=66)	High (n) (%) (N=42)	
Age (yrs)	≤ 60	37	25 (67.6)	12 (32.4)	0.32
	> 60	71	41 (57.7)	30 (42.3)	
Sex	Female	43	28 (65.1)	15 (34.9)	0.48
	Male	65	38 (58.5)	27 (41.5)	
DLBCL subtype (n=107)	GC	49	27 (55.1)	22 (44.9)	0.27
	ABC/non-ABC	58	38 (65.5)	20 (33.5)	
Volume (cm)	≤ 10	87	54 (62.1)	33 (37.9)	0.68
	>10	21	12 (57.1)	9 (42.9)	
Tumor site	Nodal	53	31 (58.5)	22 (41.5)	0.85
	Extranodal disease	6	4 (66.7)	2 (33.3)	
	Both	49	31 (63.3)	18 (36.7)	
No. of extranodal sites	≤1	97	59 (60.8)	38 (39.2)	0.85
	>1	11	7(63.6)	4 (36.4)	
Stages	1	26	13 (50)	13 (50)	0.24
	2	25	13 (52)	12 (48)	
	3	24	17 (70.8)	7 (29.2)	
	4	33	23 (69.7)	10 (30.3)	
B symptoms (n=106)	Absent	52	30 (57.7)	22 (42.3)	0.45
	Present	54	35 (64.8)	19 (35.2)	

Pretreated LDH	Normal < 450	50	30 (60)	20 (40)	0.83
	Raised	58	36 (62.1)	22 (37.9)	
Extranodal site	≤ 1 extranodal site	53	31 (58.5)	22 (41.5)	0.58
	>1 extranodal site	55	35 (63.6)	20 (36.4)	
Stages (Advanced and lower stages)	Advanced (3&4 stages)	57	40 (70.2)	17 (29.8)	0.041*
	Early stages (1&2)	51	26 (51)	25 (49)	
ECOG (n=105)	0	67	38 (56.7)	29 (43.3)	**
	1	27	18 (66.7)	9 (33.3)	
	2	7	5 (71.4)	2 (28.6)	
	3	3	1 (33.3)	2 (66.7)	
	4	1	1 (100)	0 (0)	
ECOG >2 (n= 105)	ECOG ≤2	94	56 (59.5)	38 (40.5)	0.79
	ECOG >2	11	7 (63.6)	4 (36.4)	
R-IPI	Good	77	43 (55.8)	34 (44.2)	0.099
	Poor	31	23 (74.2)	8 (25.8)	

ECOG Status: 0 - The patient has no symptoms 1 - The patient had symptoms but is ambulatory 2 - The patient is bedridden less than half the day 3 - The patient is bedridden half the day or longer 4 - The patient is chronically bedridden and requires assistance with the activities of daily living

*p value < 0.05

** p value couldn't be calculated due to small number of patients in each group